Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients

Cancer Letters

Volumn 370, Issue 2, 2016, Pages 324-331

  Xu, Song ^a   Lou, Feng ^c   Wu, Yi ^a   Sun, Da Qiang ^b   Zhang, Jing Bo ^c   Chen, Wei ^c   Ye, Hua ^c   Liu, Jing Hao ^a   Wei, Sen ^a   Zhao, Ming Yu ^c   Wu, Wen Jun ^c   Su, Xue Xia ^c   Shi, Rong ^c   Jones, Lindsey ^d   Huang, Xue F ^d   Chen, Si Yi ^d   Chen, Jun ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN CHEST HOSPITAL   (China)

^c San Valley Biotechnology Incorporated   (China)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Circulating tumor DNA; Ion PGM AmpliSeq cancer panel; Next generation sequencing; NSCLC; Targeted sequencing

Indexed keywords

CIRCULATING TUMOR DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; TISSUE DNA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER STAGING; CHINA; CIRCULATING TUMOR DNA BLOOD LEVEL; CLINICAL ARTICLE; DNA DETERMINATION; DNA ISOLATION; DNA SEQUENCE; EGFR GENE; FEASIBILITY STUDY; FEMALE; GENE; GENE MUTATION; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; PIK3CA GENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; BLOOD; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING;

EID: 84949523228     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.11.005     Document Type: Article

References (38)

1. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol 2005, 23:5900-5909.
2. Ludovini V., Bianconi F., Pistola L., Chiari R., Minotti V., Colella R., et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J. Thorac. Oncol 2011, 6:707-715.
3. Tsao M.S., Aviel-Ronen S., Ding K., Lau D., Liu N., Sakurada A., et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J. Clin. Oncol 2007, 25:5240-5247.
4. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med 2005, 352:786-792.
5. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
6. Tan D.S., Camilleri-Broet S., Tan E.H., Alifano M., Lim W.T., Bobbio A., et al. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics. Int. J. Cancer 2014, 135:1092-1100.
7. Kuiper J.L., Heideman D.A., Thunnissen E., Paul M.A., van Wijk A.W., Postmus P.E., et al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer 2014, 85:19-24.
8. Majem M., Remon J. Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. Transl. Lung Cancer Res 2013, 2:226-237.
9. Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med 2014, 6:224ra224.
10. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.-D., et al. DNA Fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665.
11. Sozzi G., Conte D., Leon M., Cirincione R., Roz L., Ratcliffe C., et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J. Clin. Oncol 2003, 21:3902-3908.
12. Kimura H., Suminoe M., Kasahara K., Sone T., Araya T., Tamori S., et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br. J. Cancer 2007, 97:778-784.
13. Stroun M., Maurice P., Vasioukhin V., Lyautey J., Lederrey C., Lefort F., et al. The origin and mechanism of circulating DNA. Ann. N. Y. Acad. Sci 2000, 906:161-168.
14. Murtaza M., Dawson S.J., Tsui D.W., Gale D., Forshew T., Piskorz A.M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497:108-112.
15. Spindler K.-L.G., Pallisgaard N., Andersen R.F., Jakobsen A. Changes in mutational status during third-line treatment for metastatic colorectal cancer - results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int. J. Cancer 2014, 135:2215-2222.
16. Douillard J.-Y., Ostoros G., Cobo M., Ciuleanu T., Cole R., McWalter G., et al. Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J. Thorac. Oncol 2014, 9:1345-1353.
17. Taniguchi K., Uchida J., Nishino K., Kumagai T., Okuyama T., Okami J., et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res 2011, 17:7808-7815.
18. Kim H.-R., Lee S.Y., Hyun D.-S., Lee M.K., Lee H.-K., Choi C.-M., et al. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J. Exp. Clin. Cancer Res 2013, 32:50.
19. Kukita Y., Uchida J., Oba S., Nishino K., Kumagai T., Taniguchi K., et al. Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS ONE 2013, 8:e81468.
20. Narayan A., Carriero N.J., Gettinger S.N., Kluytenaar J., Kozak K.R., Yock T.I., et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res 2012, 72:3492-3498.
21. Newman A.M., Bratman S.V., To J., Wynne J.F., Eclov N.C.W., Modlin L.A., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med 2014, 20:548-554.
22. Couraud S., Vaca-Paniagua F., Villar S., Oliver J., Schuster T., Blanché H., et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin. Cancer Res 2014, 20:4613-4624.
23. Forshew T., Murtaza M., Parkinson C., Gale D., Tsui D.W., Kaper F., et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med 2012, 4:136ra168.
24. Chan K.C.A., Jiang P., Zheng Y.W.L., Liao G.J.W., Sun H., Wong J., et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem 2013, 59:211-224.
25. Madic J., Kiialainen A., Bidard F.-C., Birzele F., Ramey G., Leroy Q., et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int. J. Cancer 2015, 136:2158-2165.
26. Bai X., Zhang E., Ye H., Nandakumar V., Wang Z., Chen L., et al. PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing. PLoS ONE 2014, 9:e99306.
27. Xu Z., Huo X., Tang C., Ye H., Nandakumar V., Lou F., et al. Frequent KIT mutations in human gastrointestinal stromal tumors. Sci. Rep.-UK 2014, 4:5907.
28. Cai X., Sheng J., Tang C., Nandakumar V., Ye H., Ji H., et al. Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing. PLoS ONE 2014, 9:e95228.
29. Fisher R., Pusztai L., Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br. J. Cancer 2013, 108:479-485.
30. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med 2012, 366:883-892.
31. Yap T.A., Gerlinger M., Futreal P.A., Pusztai L., Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl. Med 2012, 4:127ps110.
32. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
33. Kumar S., Guleria R., Singh V., Bharti A.C., Mohan A., Das B.C. Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer. Eur. Respir. J. 2010, 36:885-892.
34. Schmid K., Oehl N., Wrba F., Pirker R., Pirker C., Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin. Cancer Res 2009, 15:4554-4560.
35. Goto K., Ichinose Y., Ohe Y., Yamamoto N., Negoro S., Nishio K., et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J. Thorac. Oncol 2012, 7:115-121.
36. Isobe K., Hata Y., Kobayashi K., Hirota N.A.O., Sato K., Sano G.O., et al. Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. Anticancer Res 2012, 32:3339-3344.
37. Oxnard G.R., Arcila M.E., Sima C.S., Riely G.J., Chmielecki J., Kris M.G., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin. Cancer Res 2011, 17:1616-1622.
38. Kimura T., Holland W.S., Kawaguchi T., Williamson S.K., Chansky K., Crowley J.J., et al. Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann. N. Y. Acad. Sci 2004, 1022:55-60.